<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02631863</url>
  </required_header>
  <id_info>
    <org_study_id>FDZJALA-201510</org_study_id>
    <nct_id>NCT02631863</nct_id>
  </id_info>
  <brief_title>Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)</brief_title>
  <official_title>A Pilot Study of Photodynamic Therapy (PDT) Using Aminolaevulinic Acid (ALA) in Patients With HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study the effectiveness of photodynamic therapy with aminolaevulinic acid for
      the treatment of patients with HPV+ low grade cervical intraepithelial neoplasia (LSIL;CIN1).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>3 months after treatments</time_frame>
    <description>Based on histology, cytology and HPV status. &quot;Response&quot; is defined as: 1) pathology and cytology were both normal; 2) pathology and/or cytology showed low grade and the baseline HPV infection was cleared.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>3 months after treatments</time_frame>
    <description>Based on histology, cytology and HPV status. &quot;Complete response&quot; is defined as normal pathology, normal cytology and negative HPV.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance of high risk HPV</measure>
    <time_frame>3 months after treatments</time_frame>
    <description>Proportion of patients with high risk HPV clearance</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <condition>Low-Grade Squamous Intraepithelial Lesions</condition>
  <condition>Papillomavirus Infections</condition>
  <arm_group>
    <arm_group_label>ALA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 3 topical treatments of aminolaevulinic acid 500mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive 3 topical treatments of placebo 500mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aminolaevulinic acid</intervention_name>
    <description>Aminolaevulinic acid with illumination</description>
    <arm_group_label>ALA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo with illumination</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal women, 25-50 years of age

          -  Diagnosed with LSIL/CIN1 by local pathology (biopsy) and high-risk HPV positive by HC2
             assay within the last 3 months

          -  Satisfactory colposcopy examination (visibility of entire transformation zone and
             entire lesion margin )

          -  Meet the following conditions: pregnancy test negative; no pregnancy plan during the
             trial; no sexuality or reliable contraceptive measures taken since last menstruation
             to the onset of the study, agreeing to adopt reliable contraceptive measures during
             the study

          -  Written informed consent signed

        Exclusion Criteria:

          -  ASC-H (atypical squamous cells, cannot exclude HSIL) or HSIL (high-grade squamous
             intraepithelial lesions) or AGC (atypical glandular cells) or AIS (adenocarcinoma in
             situ) on cytology, or malignant cells on cytology or histology, or other suspicion of
             either micro-invasive or invasive disease

          -  Invasive carcinoma possibility or lesions extending to the vaginal vault or suspicion
             of endocervical disease on colposcopy

          -  Severe pelvic inflammatory disease, severe cervicitis, or other severe gynaecological
             infection as per clinical examination

          -  Undiagnosed vaginal bleeding

          -  With allergic disease at present; known or suspected porphyria; known allergy to ALA
             or analogues

          -  With serious cardiovascular, neurologic, psychiatric, endocrine, hematological
             disease; immunocompromised conditions; patients with malignant tumors

          -  Hepatic or renal functions abnormal (alanine aminotransferase or aspartate
             transaminase or total bilirubin &gt; 1.5 upper limit of normal [ULN], or serum creatinine
             or blood urea nitrogen &gt; 1.5 ULN)

          -  Pregnancy or nursing

          -  Previous physical therapy of LSIL/CIN1 after pathologic diagnosis

          -  Participation in any clinical studies within the last 30 days

          -  Subjects that the investigators judged to be not suitable to participate the study
             besides above
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beihua Kong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Youzhong Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jining Tao</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jining Tao</last_name>
    <email>jntao@d-zj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Obstetrics &amp; Gynecology Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Women's Hospital School of Medicine Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2015</study_first_submitted>
  <study_first_submitted_qc>December 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Squamous Intraepithelial Lesions of the Cervix</mesh_term>
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

